Literature DB >> 17393018

Haemostatic activation in post-menopausal women taking low-dose hormone therapy: less effect with transdermal administration?

Jeanette F Brosnan1, Brian L Sheppard, Lucy A Norris.   

Abstract

Hormone therapy (HT) increases the risk of cardiovascular and thromboembolic disease in post-menopausal women. Recent studies have suggested that prothrombotic mechanisms are likely to be involved. Transdermal HT avoids the first-pass effect of oestrogen in the liver and may have a less marked effect on the haemostatic system than equivalent oral preparations. The majority of studies have compared HT preparations that have different formulations as well as routes of administration. We investigated changes in the haemostatic system in post-menopausal women using two pharmacologically similar HT preparations, which differed only in their route of administration. Three hundred forty-four healthy post-menopausal women were randomised to six months treatment with either a transdermal matrix patch containing 25 microg 17beta-estradiol/125 microg norethisterone acetate (NETA) applied every 3-4 days, or an equivalent oral preparation (estradiol 1 mg and NETA 0.5 mg given once daily). Oral treatment significantly reduced fibrinogen (p < 0.003), factor VIIc (FVIIc) (p < 0.00001), and antithrombin (AT) levels (p < 0.005); the effects in the transdermal group were less marked with no reduction in fibrinogen levels and lesser effect on FVIIc (p < 0.03) compared with oral treatment. Treatment type significantly affected fibrinolysis with lower plasmin-anti-plasmin (PAP) levels in the transdermal group (p < 0.003) and lower plasminogen activator inhibitor-1 antigen (PAI-1) (p < 0.012) and tissue plasminogen activator (tPA) antigen levels in the oral group (p < 0.002). Prothrombin fragment 1.2 and activated protein C (APC) resistance were not affected by either treatment. Transdermal HT has a less marked effect on coagulation than an equivalent oral preparation. Randomised trials are required to investigate whether this translates into less risk of cardiovascular and thromboembolic disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17393018

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  13 in total

Review 1.  Impact of sex hormone metabolism on the vascular effects of menopausal hormone therapy in cardiovascular disease.

Authors:  Durr-e-Nayab Masood; Emir C Roach; Katie G Beauregard; Raouf A Khalil
Journal:  Curr Drug Metab       Date:  2010-10       Impact factor: 3.731

Review 2.  Female-specific factors for IHD: across the reproductive lifespan.

Authors:  Chrisandra Shufelt; Talya Waldman; Erica Wang; C Noel Bairey Merz
Journal:  Curr Atheroscler Rep       Date:  2015       Impact factor: 5.113

3.  Mural thrombus in the normal-appearing descending thoracic aorta of a chronic smoker.

Authors:  Habib Habib; Judy Hsu; Patricia Jo Winchell; Joseph Daoko
Journal:  Tex Heart Inst J       Date:  2013

4.  Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen.

Authors:  Marianne Canonico; Martine Alhenc-Gelas; Geneviève Plu-Bureau; Valérie Olié; Pierre-Yves Scarabin
Journal:  Menopause       Date:  2010 Nov-Dec       Impact factor: 2.953

5.  Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative Observational Study.

Authors:  Chrisandra L Shufelt; C Noel Bairey Merz; Ross L Prentice; Mary B Pettinger; Jacques E Rossouw; Vanita R Aroda; Andrew M Kaunitz; Kamakshi Lakshminarayan; Lisa W Martin; Lawrence S Phillips; Joann E Manson
Journal:  Menopause       Date:  2014-03       Impact factor: 2.953

Review 6.  Vascular actions of estrogens: functional implications.

Authors:  Virginia M Miller; Sue P Duckles
Journal:  Pharmacol Rev       Date:  2008-06-25       Impact factor: 25.468

Review 7.  Managing Menopause by Combining Evidence With Clinical Judgment.

Authors:  Chrisandra Shufelt; Joann Manson
Journal:  Clin Obstet Gynecol       Date:  2018-09       Impact factor: 2.190

8.  Oral contraceptive use and the ECG: evidence of an adverse QT effect on corrected QT interval.

Authors:  Tara Sedlak; Chrisandra Shufelt; Carlos Iribarren; Liisa L Lyon; C Noel Bairey Merz
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-05-03       Impact factor: 1.468

9.  Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women.

Authors:  Marc J Gunter; Donald R Hoover; Herbert Yu; Sylvia Wassertheil-Smoller; Thomas E Rohan; JoAnn E Manson; Barbara V Howard; Judith Wylie-Rosett; Garnet L Anderson; Gloria Y F Ho; Robert C Kaplan; Jixin Li; Xiaonan Xue; Tiffany G Harris; Robert D Burk; Howard D Strickler
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

10.  17Beta-estradiol increases basal but not bradykinin-stimulated release of active t-PA in young postmenopausal women.

Authors:  Mias Pretorius; Gary P van Guilder; Raul J Guzman; James M Luther; Nancy J Brown
Journal:  Hypertension       Date:  2008-02-07       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.